Publication:
Endoscope-enhanced fluorescence-guided microsurgery increases survival in patients with glioblastoma

dc.bibliographiccitation.journalActa Neurochirurgica
dc.contributor.authorBettag, Christoph
dc.contributor.authorSchatlo, Bawarjan
dc.contributor.authorAbboud, Tammam
dc.contributor.authorBehme, Daniel
dc.contributor.authorBock, Christoph
dc.contributor.authorvon der Brelie, Christian
dc.contributor.authorRohde, Veit
dc.contributor.authorMielke, Dorothee
dc.date.accessioned2023-12-04T22:20:06Z
dc.date.available2023-12-04T22:20:06Z
dc.date.issued2023
dc.description.abstractAbstract Purpose Extent of resection (EOR) predicts progression-free survival (PFS) and may impact overall survival (OS) in patients with glioblastoma. We recently demonstrated that 5-aminolevulinic acid-(5-ALA)-fluorescence-enhanced endoscopic surgery increase the rate of gross total resection. However, it is hitherto unknown whether fluorescence-enhanced endoscopic resection affects survival. Methods We conducted a retrospective single-center analysis of a consecutive series of patients who underwent surgery for non-eloquently located glioblastoma between 2011 and 2018. All patients underwent fluorescence-guided microscopic or fluorescence-guided combined microscopic and endoscopic resection. PFS, OS, EOR as well as clinical and demographic parameters, adjuvant treatment modalities, and molecular characteristics were compared between microscopy-only vs. endoscopy-assisted microsurgical resection. Results Out of 114 patients, 73 (65%) were male, and 57 (50%) were older than 65 years. Twenty patients (18%) were operated on using additional endoscopic assistance. Both cohorts were equally distributed in terms of age, performance status, lesion location, adjuvant treatment modalities, and molecular status. Gross total resection was achieved in all endoscopy-assisted patients compared to about three-quarters of microscope-only patients (100% vs. 75.9%, p =0.003). The PFS in the endoscope-assisted cohort was 19.3 months (CI95% 10.8–27.7) vs. 10.8 months (CI95% 8.2–13.4; p =0.012) in the microscope-only cohort. OS in the endoscope-assisted group was 28.9 months (CI95% 20.4–34.1) compared to 16.8 months (CI95% 14.0–20.9), in the microscope-only group ( p =0.001). Conclusion Endoscope-assisted fluorescence-guided resection of glioblastoma appears to substantially enhance gross total resection and OS. The strong effect size observed herein is contrasted by the limitations in study design. Therefore, prospective validation is required before we can generalize our findings.
dc.identifier.doi10.1007/s00701-023-05862-6
dc.identifier.pii5862
dc.identifier.urihttps://resolver.sub.uni-goettingen.de/purl?gro-2/139274
dc.item.fulltextWith Fulltext
dc.language.isoen
dc.notes.internDOI-Import GROB-725
dc.notes.internGefördert über DFG OAPK
dc.relation.eissn0942-0940
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleEndoscope-enhanced fluorescence-guided microsurgery increases survival in patients with glioblastoma
dc.typejournal_article
dc.type.internalPublicationyes
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
10.1007s00701-023-05862-6.pdf
Size:
586.07 KB
Format:
Adobe Portable Document Format

Collections